m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05434
 [1]
m6A modification MIR335 MIR335 METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA miR-335 ZFP36L1  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target microRNA 335 (MIR335)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator MicroRNA 335 (MIR335) microRNA View Details
Regulated Target ZFP36 ring finger protein like 1 (ZFP36L1) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary METTL3-mediated m6A methylation increases the maturation of microRNA 335 (MIR335), which promotes SG formation and reduces the apoptosis level of injury neurons and cells, and provides a potential therapeutic strategy for acute ischemic stroke. miR-335 enhanced SG formation through degradation of the mRNA of the ZFP36 ring finger protein like 1 (ZFP36L1).
Responsed Disease Acute ischemic stroke ICD-11: 8B11
 Disease Info 
Pathway Response Apoptosis hsa04210
Cell Process RNA maturation
Cell apoptosis
In-vitro Model
 PC12 Rat adrenal gland pheochromocytoma Rattus norvegicus CVCL_0481
In-vivo Model After a median incision on the neck, the left common carotid artery (CCA), internal carotid artery (ICA), and external carotid artery (ECA) were isolated. The left CCA and the ECA were ligated.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
8B11: Acute ischemic stroke 7 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name PEG-bHb-CO Phase 2 [2]
Synonyms
Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0A6LT
 Compound Name DM199 Phase 2 [3]
External Link
TTD: DS70MP
 Compound Name BIIB131 Phase 2 [4]
Synonyms
(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007
    Click to Show/Hide
External Link
CID: 50898407
TTD: DEV2G0
 Compound Name BMS-986177 Phase 2 [5]
Synonyms
Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2
    Click to Show/Hide
External Link
CID: 118277544
TTD: DB6XD8
 Compound Name SonoLysis Prolyse Phase 2 [6]
External Link
TTD: D08JGE
 Compound Name ACT017 Phase 1/2 [7]
External Link
TTD: DPG5T9
 Compound Name Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 Patented [8]
Synonyms
PMID27998201-Compound-16
    Click to Show/Hide
External Link
CID: 1720818
TTD: D0UX4J
References
Ref 1 Methyltransferase 3 Mediated miRNA m6A Methylation Promotes Stress Granule Formation in the Early Stage of Acute Ischemic Stroke. Front Mol Neurosci. 2020 Jun 5;13:103. doi: 10.3389/fnmol.2020.00103. eCollection 2020.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 ClinicalTrials.gov (NCT04123613) Multiple Doses of DM199 in Patients With Chronic Kidney Disease. U.S. National Institutes of Health.
Ref 4 ClinicalTrials.gov (NCT05764122) A Multicenter, Operationally Seamless, Double-Blind, Dose-Ranging, Placebo-Controlled, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Intravenous BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well. U.S.National Institutes of Health.
Ref 5 ClinicalTrials.gov (NCT03766581) A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (AXIOMATIC-SSP). U.S. National Institutes of Health.
Ref 6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004567)
Ref 7 ClinicalTrials.gov (NCT03803007) Acute Ischemic Stroke Interventional Study (ACTIMIS). U.S. National Institutes of Health.
Ref 8 Cathepsin B and L inhibitors: a patent review (2010 - present). Expert Opin Ther Pat. 2017 Jun;27(6):643-656. doi: 10.1080/13543776.2017.1272572. Epub 2016 Dec 23.